MedTrace Logo

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

NCT06105554 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-02-18

No results posted yet for this study

Summary

Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM.

Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.

Conditions

Interventions

DRUG

Belumosudil mesylate

Given by PO

Sponsors & Collaborators

  • Sanofi US Services, Inc

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Robert Orlowski, M D · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-30
Primary Completion
2027-08-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06105554 on ClinicalTrials.gov